Stopping Medical Research to Save Money: A Broken Pact with Researchers and Patients

JAMA

Volumn 289, Issue 16, 2003, Pages 2128-2131

  Psaty, Bruce M ^a   Rennie, Drummond ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; DOXORUBICIN; HYDROCHLOROTHIAZIDE; PACLITAXEL; VERAPAMIL; ANTIHYPERTENSIVE AGENT; BENZOTHIADIAZINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

BUDGET; CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EDITORIAL; ETHICS; HUMAN; INVESTMENT; MEDICAL RESEARCH; OUTCOMES RESEARCH; PATIENT RIGHT; PRIORITY JOURNAL; PROFIT; PUBLICATION; BIOMEDICAL AND BEHAVIORAL RESEARCH; ECONOMICS; HYPERTENSION; NOTE; OUTCOME ASSESSMENT; STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DIURETICS; DRUG INDUSTRY; HUMANS; HYPERTENSION; OUTCOME ASSESSMENT (HEALTH CARE); SODIUM CHLORIDE SYMPORTER INHIBITORS; VASODILATOR AGENTS; VERAPAMIL;

EID: 0037514264     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.16.2128     Document Type: Editorial

References (21)

1. Black HR, Elliott WJ, Grandits G, et al, for the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA. 2003;289:2073-2082.
2. Baird P, Downie J, Thompson J. Clinical trials and industry. Science. 2002;297:2211.
3. Thompson J, Baird P, Downie J. The Olivieri Report. Toronto, Ontario: James Lorimer & Co Ltd; 2001:26.
4. Rennie D. Thyroid storm. JAMA, 1997;277:1238-1243.
5. A curious stopping rule from Hoechst Marion Roussel. Lancet. 1997;350:155.
6. Viberti GC, Slama G, Pozza G, Cryzyk A, Bilous RW, Gries A. Early closure of European Pimagedine trial. Lancet. 1997;350:214-215.
7. Langer A, Hopf G. Early stopping of trials. Lancet. 1997;350:890-891.
8. Shenoi A, Nagesh NK, Maiya PP, Bhat SR, Rao SDS. Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis. Indian Pediatr. 1999;36:1113-1118.
9. Lièvre M, Menard J, Bruckert E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001;322:603-606.
10. Pergolizzi JV. Early termination: conflicts and concerns. Clin Res, 2002;2:4-5.
11. Food and Drug Administration, Department of Health and Human Services. International Conference on Harmonization: guidance on statistical principles for clinical trials, availability, 63 Federal Register 49452, 49583-49598 (1998).
12. Ashcroft R. Responsibilities of sponsors are limited in premature discontinuation of trials. BMJ. 2001;323:53.
13. Schron EB, Wassertheil-Smoller S, Pressel S. Clinical trial participant satisfaction: survey of SHEP enrollees. J Am Geriatr Soc. 1997;45:934-938.
14. Mattson ME, Curb JD, McArdle R. Participation in a clinical trial: the patients' point of view. Control Clin Trials. 1985;6:156-167.
15. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from the Heath Examination Surveys, 1960-1991. Hypertension. 1995;26:60-69.
16. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: The Cardiovascular Health Study. Arch Intern Med. 2002;162:2325-2332.
17. World Medical Association Declaration of Helsinki. Ethical principals for medical research involving human subjects. JAMA. 2000;284:3043-3045.
18. Boyd K. Commentary: early discontinuation violates Helsinki principles. BMJ. 2001;322:605-606.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
20. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
21. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999;282:786-790.